



## Antiviral Approaches, Immunological Interventions and Vaccination for Effective Virus Spread Control and Prevention

Guest Editors:

### Dr. Milene Dias Miranda

1. Laboratório de Morfologia e Morfogênese Viral, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
2. Programa de Pós-Graduação em Biologia Celular e Molecular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

### Dr. Cristiana Couto Garcia

1. Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil
2. Laboratório de Vírus Respiratórios, Exantemáticas e Emergências Virais, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

### Message from the Guest Editors

Viral agents represent one of the main groups of pathogens causing morbidity and mortality in humans. Most of these potential agents cause major epidemics and pandemics, as we have seen recently with SARS-CoV-2. The prevention and control of viral spread are highly desirable. In this sense, we encourage the submission of manuscripts with promising results in the research field of antiviral and vaccines, including but not limited to (1) traditional inactivated or live attenuated vaccines, virus-vectored, subunit, viral-like particle, nucleic acid-based vaccine development; (2) new or repurposed molecules that can act directly against the viruses or modulate molecules of the immune system involved in the pathogenesis of viral pathogens of high clinical relevance.

Deadline for manuscript submissions:

**closed (30 June 2025)**



[mdpi.com/si/179727](https://mdpi.com/si/179727)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)